Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: ANIP

ANI Pharmaceuticals, Inc.

Healthcare | Drug Manufacturers - Specialty & Generic

No licensed closing price on file for ANIP. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$4.60

ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) is a specialty and generic drug manufacturer. Figures from SEC EDGAR; updated 2026-10-20 07:13 UTC.

What ANI Pharmaceuticals, Inc. does

ANI Pharmaceuticals develops, manufactures, and commercializes therapeutics through three business segments: Rare Disease, Generics, and Brands. The company operates pharmaceutical manufacturing facilities in Minnesota and New Jersey capable of producing oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products.

Summarized from ANI Pharmaceuticals, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Key facts

Valuation
EPS (TTM)$4.60
Return on equity14.49%
Debt/equity0.47

Revenue, margins & earnings

FY2021: net loss $43M on revenue $216M$216MFY2021FY2022: net loss $48M on revenue $316M$316MFY2022FY2023 Net income: $19MFY2023 Taxes & interest: $28MFY2023 Operating costs: $440M$487MFY2023FY2024: net loss $19M on revenue $614M$614MFY2024FY2025 Net income: $78MFY2025 Taxes & interest: $33MFY2025 Operating costs: $772M$883MFY2025
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-10-16
  • 2026-10-16PRESIDENT & CEOSale-5,400$388.2K
  • 2026-10-13SR. VP, GENERAL COUNSEL & SEC.Sale-500$36.8K
  • 2026-09-30SVP & CFOSale-2,850$208.1K
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does ANI Pharmaceuticals, Inc. do?

ANI Pharmaceuticals develops, manufactures, and commercializes therapeutics through three business segments: Rare Disease, Generics, and Brands.

When did ANIP last file with the SEC?

ANI Pharmaceuticals, Inc.'s most recent SEC filing on record is a 8-K filed 2026-08-24. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 07:13 UTC. This page is also available as JSON at /api/data?ticker=ANIP and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for ANIP and 5,000+ tickers.

Create a free account — keep ANIP
For your agent
GET /api/data?ticker=ANIP

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt